Lung Cancer Clinical Trial
Official title:
Phase II Trial Comparing 4-Dimensional Computed Tomography Derived Ventilation Versus SPECT/CT Tc-99m Aerosol Ventilation in Patients With Thoracic Malignancies
Objectives:
Primary Objective:
1. To determine the correlation between 4-dimensional computed tomography (4D CT) derived
ventilation and single photon emission tomography (SPECT) aerosol Tc-99m determined
ventilation.
Secondary Objective:
1. To evaluate the reproducibility of the 4D CT derived ventilation and to obtain an
estimate of the variance in a single setting.
2. To assess the correlation between hypoperfused and hypoventilated pulmonary regions in
patients with thoracic malignancies.
3. To investigate the effect of continuous positive airway pressure (CPAP) on ventilation
and tumor motion.
By using a 4-dimensional (4D) computed tomography (CT) scans researchers will create
ventilation (circulation of air) calculations. This new calculation method is quicker and may
produce better images than the standard ventilation calculations.
If you agree to take part in this study and are found to be eligible, you will have lung
function imaging. Lung function imaging gives researchers information on how well the lungs
work, how air moves into the lungs with breathing, and blood circulation into the lungs.
You will have three 4D CT scans performed while you are breathing quietly. A 2-inch plastic
box will be placed on top of your chest to monitor the motion of your chest during the
scanning. After you are out of the CT scanner (once the scanning is finished), ventilation
images are calculated from the 4D CT images and will be compared with the standard
ventilation imaging method. The 4D CT imaging will take about 30 minutes to complete.
As part of standard care, once you have finished the 4D CT scan, you will have a single
photon emission computed tomography (SPECT) pulmonary (lung) ventilation scan performed. The
SPECT ventilation scan requires that you first breathe in a radioactive aerosol (or mist,
called Tc-99m DPTA), which will help the study doctor tell where air goes when you breathe.
Then you will be placed in the SPECT scanner, and images will be taken of your lungs. The
SPECT imaging will take about 1 hour to complete.
Within 10 days after the first imaging session, you will return for a second imaging session.
During the second imaging session, you will have a standard of care SPECT pulmonary perfusion
(blood supply to tissue and organs) test done. During this test, a radioactive substance is
given by vein (called Tc-99m MAA). This substance will get trapped in the lungs, and the
SPECT imaging will show the blood flow in the lungs. This test should take 45-60 minutes to
complete.
Once you complete the second imaging session, your participation will over in this study.
This is an investigational study. All of the imaging scans used in this study are FDA
approved and commercially available. The calculation of ventilation images from 4D CT
scanning is investigational and authorized for use in research only. Up to 36 patients will
take part in this study. All will be enrolled at M. D. Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|